CRISPR Therapeutics AG (CRSP)
43.44
+0.30 (+0.68%)
USD |
NASDAQ |
Mar 24, 16:00
43.43
0.00 (0.00%)
After-Hours: 18:12
CRISPR Therapeutics Net Income (TTM): -650.18M for Dec. 31, 2022
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2022 | -650.18M |
| September 30, 2022 | -680.85M |
| June 30, 2022 | -633.45M |
| March 31, 2022 | 311.61M |
| December 31, 2021 | 377.66M |
| September 30, 2021 | 411.87M |
| June 30, 2021 | 446.58M |
| March 31, 2021 | -392.30M |
| December 31, 2020 | -348.86M |
| September 30, 2020 | -211.28M |
| June 30, 2020 | 19.58M |
| March 31, 2020 | 45.54M |
| December 31, 2019 | 66.86M |
| September 30, 2019 | -11.27M |
| Date | Value |
|---|---|
| June 30, 2019 | -200.41M |
| March 31, 2019 | -185.09M |
| December 31, 2018 | -164.98M |
| September 30, 2018 | -117.25M |
| June 30, 2018 | -91.25M |
| March 31, 2018 | -75.18M |
| December 31, 2017 | -68.36M |
| September 30, 2017 | -51.40M |
| June 30, 2017 | -41.39M |
| March 31, 2017 | -36.24M |
| December 31, 2016 | -23.20M |
| September 30, 2016 | -52.59M |
| June 30, 2016 | -44.25M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-680.85M
Minimum
Sep 2022
446.58M
Maximum
Jun 2021
-104.13M
Average
-104.25M
Median
Net Income (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.322B |
| Intellia Therapeutics Inc | -474.19M |
| Beam Therapeutics Inc | -289.09M |
| Editas Medicine Inc | -220.43M |
| AC Immune SA | -74.24M |